清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Abstract 37: Novel antibody-drug conjugates targeting ADAM9-expressing solid tumors demonstrate potent preclinical activity

作者
Stuart W. Hicks,Nicholas C. Yoder,Deryk T. Loo,Asli Muvaffak,Yinghui Zhou,Megan E. Fuller,Molly A. McShea,Marian Themeles,Katherine H. Mucciarone,Juniper A. Scribner,Bhaswati Barat,Thomas Sun,James K. Tamura,Francine Z. Chen,Kerry A. Donahue,Tom Chittenden
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:77 (13_Supplement): 37-37 被引量:4
标识
DOI:10.1158/1538-7445.am2017-37
摘要

Abstract ADAM9, also known as MDC9 or meltrin-γ, is a member of the ADAM (a disintegrin and metalloproteinase) family of proteases, which have been implicated in cytokine and growth factor shedding, and cell migration. Dysregulation of ADAM9 has been implicated in tumor progression and metastasis, as well as pathological neovascularization. ADAM9 overexpression has been shown to correlate with poor prognosis in prostate, renal, and pancreatic cancers. Using an immunization approach in which antibodies were raised to fetal progenitor and stem-like cancer cell lines followed by screening on tumor and normal tissues, we identified ADAM9 as a promising cell surface tumor target. FFPE-IHC expression analysis revealed that ADAM9 is overexpressed in multiple solid tumor indications relative to corresponding normal tissues. The overexpression of ADAM9 in tumors coupled with its restricted expression in normal tissues make ADAM9 an attractive target for antibody-drug conjugate (ADC) therapy. Here, we describe two ADCs both of which are based on a high affinity anti-ADAM9 antibody to selectively target ADAM9-expressing tumors. The first ADC utilizes the maytansine-derived microtubule disruptor, DM4, linked via a hindered disulfide hydrophilic linker (sulfo-SPDB). The second ADC exploits an ultra-potent DNA alkylating payload, DGN549, which is conjugated to two engineered cysteines via a peptide linker. Both conjugates bound with similar subnanomolar affinity to ADAM9-expressing cells. In vitro cytotoxicity studies showed that anti-ADAM9 ADCs can kill a broad panel of ADAM9-positve tumor cell lines, including lung, pancreatic, renal, prostate, and colon tumor cell lines. In particular, the anti-ADAM9-DGN549 conjugate was extremely potent with IC50 values ranging from 0.1 to 65 pM and was at least 2 logs more active than a non-targeting conjugate. Surprisingly, efficient in vitro cytotoxicity was observed at ADAM9 expression levels as low as a few thousand cell surface receptors per cell. Consistent with their in vitro activity, both anti-ADAM9 ADCs displayed compelling anti-tumor activity in xenograft models. In a CaLu3 non-small cell lung cancer xenograft model, anti-ADAM9-DM4 induced tumor growth delay at a single 1.25 mg Ab/kg dose. In the same model, a single intravenous dose of 0.25 mg Ab/kg of the anti-ADAM9-DGN549 produced durable complete remissions in 8/8 mice. A non-targeting DGN549 ADC was inactive even when dosed at 10 times that of the anti-ADAM9 ADC, demonstrating that targeted delivery of DGN549 through ADAM9 binding is required for activity. These data demonstrate that anti-ADAM9 ADCs exhibit antitumor activity against a broad panel of ADAM9-positive malignancies and cause durable remissions in preclinical models at doses expected to be clinically achievable. Anti-ADAM9 ADCs represent a promising therapeutic strategy to target a wide range of ADAM9-expressing tumors. Citation Format: Stuart W. Hicks, Nicholas C. Yoder, Deryk Loo, Asli Muvaffak, Yinghui Zhou, Megan E. Fuller, Molly A. McShea, Marian Themeles, Katherine H. Mucciarone, Juniper A. Scribner, Bhaswati Barat, Thomas Sun, James Tamura, Francine Z. Chen, Kerry A. Donahue, Tom Chittenden. Novel antibody-drug conjugates targeting ADAM9-expressing solid tumors demonstrate potent preclinical activity [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 37. doi:10.1158/1538-7445.AM2017-37

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
小红书求接接接接一篇完成签到,获得积分10
7秒前
系统昵称完成签到,获得积分10
7秒前
朴实乐天完成签到,获得积分10
18秒前
HelloBOB完成签到 ,获得积分10
19秒前
25秒前
俭朴竺完成签到,获得积分10
31秒前
liangyao完成签到,获得积分20
33秒前
Tardes关注了科研通微信公众号
39秒前
41秒前
朴实惜寒完成签到,获得积分10
49秒前
11完成签到 ,获得积分10
49秒前
51秒前
king完成签到 ,获得积分10
56秒前
wsj完成签到 ,获得积分10
57秒前
Tardes发布了新的文献求助10
58秒前
ss完成签到,获得积分10
1分钟前
甜美的梦芝完成签到,获得积分10
1分钟前
西瓜柠檬可乐完成签到 ,获得积分10
1分钟前
李煜琛完成签到 ,获得积分10
1分钟前
悦耳的竺完成签到 ,获得积分10
1分钟前
搜集达人的应助被冲冲冲采纳,获得10
1分钟前
大力的安阳完成签到 ,获得积分10
1分钟前
无花果的应助被ZLPY采纳,获得30
1分钟前
1分钟前
1分钟前
刘亚梅完成签到 ,获得积分10
1分钟前
醉熏的小凡完成签到,获得积分10
1分钟前
冲冲冲发布了新的文献求助10
1分钟前
apt完成签到 ,获得积分10
1分钟前
1分钟前
忧伤的白秋完成签到,获得积分10
1分钟前
1分钟前
lx完成签到 ,获得积分10
2分钟前
天天快乐的应助被hilufite采纳,获得10
2分钟前
nhzz2023完成签到 ,获得积分10
2分钟前
和谐如彤完成签到,获得积分10
2分钟前
nanjing01完成签到 ,获得积分10
2分钟前
如泣草芥完成签到,获得积分10
2分钟前
Jessie完成签到,获得积分10
2分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8173230
求助须知:如何正确求助?哪些是违规求助? 9565593
关于积分的说明 21780536
捐赠科研通 7767429
什么是DOI,文献DOI怎么找? 3431542
关于科研通互助平台的介绍 2555764
邀请新用户注册赠送积分活动 2476697